澳大利亚的非黑素瘤皮肤癌。

Non-melanoma skin cancer in Australia.

机构信息

Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.

出版信息

Med J Aust. 2012 Nov 19;197(10):565-8. doi: 10.5694/mja12.10654.

DOI:10.5694/mja12.10654

PMID:23163687

Abstract

OBJECTIVES

To report the burden and cost of non-melanoma skin cancer (NMSC) treatments in Australia and to project estimates of numbers and costs to 2015.

DESIGN AND SETTING

Retrospective study of data obtained from Medicare Australia for NMSC treated by excision, curettage, laser or cryotherapy between 1 January 1997 and 31 December 2010, by year, sex, age group and state or territory.

MAIN OUTCOME MEASURES

Total number, total Medicare Benefits Schedule (MBS) benefit and total cost in Australian dollars of NMSC treatments.

RESULTS

The total number of NMSC treatments increased from 412 493 in 1997 to 767 347 in 2010, and we estimated that the number of treatments would increase to 938 991 (95% CI, 901 047-976 934) by 2015. The total MBS benefit for NMSC treatments in 2010 was $93.5 million, and we estimated that this will increase to $109.8 million (95% CI, $105.9-$113.7 million) by 2015, whereas the total cost with inflation (ie, cost which includes diagnosis, treatment and pathology) was $511.0 million in 2010, estimated to increase to $703.0 million (95% CI, $674.6-$731.4 million) by 2015.

CONCLUSION

NMSC treatments increased by 86% between 1997 and 2010. We anticipate that the number and the total cost without inflation of NMSC treatments will increase by a further 22% between 2010 and 2015. NMSC will remain the most costly cancer and place an increasing burden on the Australian health care system.

摘要

目的

报告澳大利亚非黑素瘤皮肤癌（NMSC）治疗的负担和成本，并预测到 2015 年的病例数和成本估算。

设计和设置

回顾性研究从澳大利亚医疗保险局获得的数据，1997 年 1 月 1 日至 2010 年 12 月 31 日期间通过切除术、刮除术、激光或冷冻疗法治疗 NMSC，按年度、性别、年龄组和州或地区进行分类。

主要观察指标

NMSC 治疗的总例数、医疗保险福利计划（MBS）总福利和澳元总成本。

结果

NMSC 治疗的总例数从 1997 年的 412493 例增加到 2010 年的 767347 例，我们预计到 2015 年，治疗例数将增加到 938991 例（95%CI，901047-976934）。2010 年 NMSC 治疗的 MBS 总福利为 9350 万美元，我们预计到 2015 年将增加到 1.098 亿美元（95%CI，1.059-1.137 亿美元），而考虑通货膨胀的总成本（即包括诊断、治疗和病理学的成本）为 2010 年的 5.11 亿美元，预计到 2015 年将增加到 7.03 亿美元（95%CI，6.746-7.314 亿美元）。